Jonah Feldman

The FDA has released a draft of new recommendations for the manufacture, development, and study design of chimeric antigen receptor T cells.

The KEYLYNK-010 trial of pembrolizumab and olaparib was terminated following negative overall survival results in patients with metastatic castration-resistant prostate cancer.

The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.

A multivariate analysis of response rates of patients with metastatic renal cell carcinoma identified which factors are associated with a partial or complete response to first-line doublet immunotherapy or immunotherapy/tyrosine kinase inhibitor combinations.

The phase 3 NuTide:121 study of acelarin was terminated due to failing to meet a primary end point of overall survival benefit.

A biotherapeutic led to improved efficacy of immunotherapy in a phase 1 study of patients with metastatic renal cell carcinoma.

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, and while many trials have failed to change the standard of care and improve outcomes, new opportunities for targeted treatment are growing, according to Brian T. Hill, MD, PhD.

The phase 2 PERICLES trial of atezolizumab with or without radiotherapy in patients with stage IV cancer did not meet its primary end point of 1-year progression-free survival.

Nathan Bahary, MD, discussed with Targeted Oncology how the cholangiocarcinoma treatment paradigm has changed and what is on the horizon for treatment and care of patients.

In an interview with Targeted Oncology, Casey M. Cosgrove, MD, discussed the current state of biomarkers for patients with endometrial cancer and how they can be used for prognostic purposes.

The MOMENTUM trial of momelotinib showed efficacy in treating symptoms of myelofibrosis, according to a press release.

Investigators of the GEMSTONE-302 trial announced finding a statistically significant benefit in overall survival with sugemalimab in patients with non–small cell lung cancer.

Sintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial.

Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.

Preliminary results from the phase 2 ERADIC trial signal promise for ibrutinib plus venetoclax for the treatment of chronic lymphocytic leukemia.

Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.

Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.

Zai Lab has announced new findings from the phase 3 PRIME trial showing efficacy in progression-free survival in patients with platinum-sensitive ovarian cancer.

The CheckMate 204 study showed overall survival benefit of combination nivolumab/ipilimumab to patients with melanoma brain metastases.

The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed recent trials and advances in neuroendocrine cancer research in an interview with Targeted Oncology for World Neuroendocrine Cancer Day.

A recently published study has shown no difference in survival outcomes for patients under 50 with colorectal cancer, despite greater treatment intensity and physical fitness.

In an interview with Targeted Oncology, Solange Peters, MD, discussed the significance of the 3-year follow-up analysis of the CheckMate 743 study of nivolumab/ipilimumab in mesothelioma.

Neeraj Agarwal, MD, spoke with Targeted Oncology about the success of the TITAN and SPARTAN studies as well as its use in real-world prostate cancer populations.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the findings from a study of rebastinib plus paclitaxel and unmet needs in the ovarian cancer setting.